JCEM data – Real world performance of the Afirma Genomic Sequencing Classifier (GSC) – a meta analysis
See more
You should use your device in portrait mode
Afirma Genomic Testing
Your molecular partner for thyroid nodule diagnosis and treatment
Thyroid nodule diagnosis is challenging and can create uncertainty.
Afirma is a comprehensive solution that helps inform personalized thyroid care for your patients.
  • Experienced

    Helping physicians individualize care for over 225,000 patients1

  • Reliable

    Consistent, reproducible performance

  • COMPREHENSIVE

    Prevent surgery in benign nodules and individualize treatment in suspicious nodules

  • CUTTING-EDGE

    Leveraging the power of RNA expression and AI/machine learning for a comprehensive answer

  • SIMPLE

    Quick answers in less than two weeks to reduce worry and wait

Afirma GenomiC
Sequencing Classifier:

Conclusively rule out surgery in the majority of patients with indeterminate nodules3

Clinically validated through a prospective, blinded, multicenter study published in JAMA Surgery3

Afirma
Xpression Atlas:

Confidently guide surgery and treatment decision using molecular findings

Afirma
Xpression Atlas:

Confidently guide surgery and treatment decision using molecular findings

Afirma
Xpression Atlas:

Confidently guide surgery and treatment decision using molecular findings

Our mission is to provide accurate molecular information to help you diagnose and create the best treatment plan for your patient

Afirma:

Count on a simplified experience

  • Veracyte is committed to providing patient access, regardless of financial situation
    • Covered by Medicare
    • Covered in-network by most commercial payers (over 275 million covered lives)
    • The Veracyte Access Program supports both eligible uninsured and commercially insured patients with financial need
  • Get answers quickly, reduce worry and wait
  • Easily manage patient reports with the Veracyte portal and mobile app
    • Access the Veracyte portal at: portal.veracyte.com
    • Download the Veracyte app from your mobile app store
Our mission is to provide accurate molecular information to help you diagnose and create the best treatment plan for your patient

Afirma:

Count on a simplified experience

  • Veracyte is committed to providing patient access, regardless of financial situation
    • Covered by Medicare
    • Covered in-network by most commercial payers (over 275 million covered lives)
    • The Veracyte Access Program supports both eligible uninsured and commercially insured patients with financial need
  • Get answers quickly, reduce worry and wait
  • Easily manage patient reports with the Veracyte portal and mobile app
    • Access the Veracyte portal at: portal.veracyte.com
    • Download the Veracyte app from your mobile app store